# Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

> **NCT07695896** · — · NOT_YET_RECRUITING · sponsor: **Yanyan Liu** · enrollment: 200 (estimated)

## Conditions studied

- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Glofitamab

## Key facts

- **NCT ID:** NCT07695896
- **Lead sponsor:** Yanyan Liu
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07695896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07695896, "Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07695896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*